(Reuters) – AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

 

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr

 

Reuters source:

https://www.reuters.com/article/us-astrazeneca-lynparza-china/astrazeneca-merck-lynparza-wins-approval-in-china-for-ovarian-cancer-treatment-idUSKBN1Y90LX